1. Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S213-S222. doi: 10.1093/cid/ciy1079.

Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.

Tulkens PM(1), Van Bambeke F(1), Zinner SH(2).

Author information: 
(1)Louvain Drug Research Institute, Université catholique de Louvain, Brussels,
(2)Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts.

Fluoroquinolones have been in clinical use for over 50 years with significant
efficacy. However, increasing resistance and emergence of some marked adverse
events have limited their usage. The most recently approved class member,
delafloxacin, is the only available anionic (non-zwitterionic) fluoroquinolone.
Its unique molecular structure provides improved in vitro activity against most
Gram-positive pathogens, including quinolone-resistant strains, which is further 
enhanced at acid pH. Delafloxacin shows favorable pharmacological properties,
with about 60% bioavailability after oral administration, only mild inhibition of
cytochrome P450 3A, and no evidence of cardiac- or phototoxicity in healthy
volunteers (tested against positive controls). Its twice daily dosing,
suitability for intravenous, oral, or switch dosing, the lack of many clinically 
significant drug-drug interactions, and acceptable adverse event profile in
registration clinical trials supports its use in the treatment of acute bacterial
skin and skin structure infections, and potentially in other infections, where
resistance to other agents, safety, and/or the need for early discharge is of

© The Author(s) 2019. Published by Oxford University Press for the Infectious
Diseases Society of America.

DOI: 10.1093/cid/ciy1079 
PMID: 30957164